In addition, engineered variants of TRAIL, containing specific amino acid changes leading to specific targeting of TRAIL-R1 or TRAIL-R2 have been designed and have shown improved anti-tumour effects in-vitro and in-vivo when compared to wild-type TRAIL [22–27]. This evidence concerns the gene TNFSF10 and neoplasm.